Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product pipeline consists of a […]
Related Keywords
California , United States , Robertw Baird , , Cardiff Oncology Inc , Morgan Stanley , Trovagene Inc , Zacks Investment Research , Renaissance Technologies , Janus Henderson Group , Cardiff Oncology Company Profile Get Rating , Maxim Group , Cardiff Oncology , Get Rating , Oncology Inc , Henderson Group , Oncology Company Profile , Polo Like Kinase , Nasdaq Crdf , Acrdf , Medical , Upgrade ,
comparemela.com © 2020. All Rights Reserved.